Dear Sir: I have read with great interest the paper by Wang et al. 1 comparing the Korean Medication Algorithm for Depressive Disorder (KMAD) with other treatment guidelines (TGs) from different academic societies across the world.
Herein I would like to complement and update the authors' perspectives with presentation of more wide range of TGs, the position of TGs and their role for clinical practice. Evidencebased and informed clinical decision-making process will clearly improve treatment outcomes. In this context, TG is systematically developed and intended to give a huge help for clinicians' and patients' prudent decisions at specific clinical circumstances. Currently the role of TG has been dramatically increased and also considered highly crucial in establishment and reformation of optimal health policy by government and insurance company as well as being an efficient and proven scientific base leading to the continuum of best care. [2] [3] [4] In fact, improved treatment outcomes with guideline-based care have been consistently reported compared to routine treatment. 5 For instance, an algorithm based care for depression based on the Texas Medication Algorithm Project (TMAP) in the U.S. 6 was compared to treatment as usual (TAU) in 12 clinics over 12 months in U.S. The TMAP-based intervention was associated with significantly better clinical outcomes than TAU.
As Wang et al. 1 stated, Korean psychiatrists need to fix and advance the KMAD in comparison with those from other countries. However, in this context, the most update TG version, different regulatory authority' s stance to approval of medication and public health insurance system as well as different social and cultural backgrounds in individual countries or regions, have to be implemented. 10 Excluding TMAP from expert consensus (EC), others are all evidence-based, the later ones are more convincing than the former one. EC is also partly from evidence but it has not been considered true evidence since the reliable criteria for expert selection is not based on scientific ways and the opinions are totally from personal experiences. The most updated TG has been performed by the WFSBP, which has been already revised in 2013, 11 thus the WFSBP 2007 10 is not the right citation. In WFSBP 2013 revision, some updates are available as followings: regarding antidepressant (AD) monotherapy vs. combination therapy, the results from COMED study 12 had been cited without clear recommendations; the specific response criteria for antidepressant treatment has been given; early improvement concept has been also introduced without specific recommendation; newer AD such as agomelatine data has been also given and incorporated and the WFSBP 2013 now recommends the use of quetiapine and aripiprazole for patients those who failed to show response to AD monothrapy regardless of presence of the psychotic symptoms. In addition, all guidelines cited in Wang et al's paper1 do not recommend the initial trial of AD for mild depression but recommend a brief psychotherapy or even just simple counselling against their assertion; AD is usually recommended for moderate to severe depression. Likewise, other missed or wrong points exists somewhere in Wang et al. 's paper. It is also unclear why they did not cite the TGs from the British (BAP 2008) 13 15 if depression is still resistant to treatment after dose adjustment and re-evaluation of proper diagnosis, the second-line strategies may include switching to tricyclic ADs (TCAs) and combining AD with another AD or a mood stabilizer, but not include antipsychotics as augmentation agents (AAs). Despite TCAs are shown as a second-line treatment in the TG, TCAs are often employed as first-line agents due to new ADs availability and cost issues in China. As for Japanese TG, 16 antipsychotics are not also included as routine AA, even if patient had psychotic depression, antipsychotics are only allowed upon agitation plus suicidal risk, the first agent is amoxapine for psychotic depression without such symptoms. Despite other strategic ways for moderate to severe depression are relatively similar to other TGs, the Japanese TGs have 3 different treatment algorithms for each specific purpose. 17 Another point is that relatively less emphasis placed on antipsychotics for augmentation on the BAP 2008, DGPPN 2010 and WFSBP 2007 TGs, may reflect that the availability of a body of evidence at the time of the TG development is highly important. In fact, quetiapine XR was approved by the European Medicines Agency (EMA) in April 2010; however, aripiprazole has not yet been approved for treating depression in Europe; indeed the manufacturer Otsuka withdrew its filing to the EMA due to long-term data issue on 2011. Likewise aripiprazole augmentation for depression has been just approved on 2013 in Japan, even the drug was developed in Japan. Given aforementioned, the principal differences of TGs among countries or regions may stem from the availability of high quality data, viewpoint of regulatory authority, availability of certain drug with approved indication, national health insurance policy including reimbursement system, promotional activity of pharmaceutical company and medical cost at the time of TG documentation.
In conclusion, the potential benefits of TGs are only as good as the quality of themselves. Clear and proper methodologies, rigorous strategies and exchangeable criticism on TG data under consideration are more important in the TG development process than rapid establishment of recommendations. 18 The effectiveness of TG implementation must also be assessed, regularly updated and given a wide range of public feedback to be validated. Additionally, a concise version of the guideline should be developed for easy, convenient and wide application for clinicians in busy routine practice.
